NCT03809052View on ClinicalTrials.gov

A First in Human Study to Evaluate the Safety, Tolerability and PK of GB1211 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

January 14, 2019

Primary Completion Date

June 25, 2019

Study Completion Date

June 25, 2019

Conditions
Safety and Tolerability
Interventions
DRUG

GB1211

Hard capsules for oral use

DRUG

Placebo

Hard capsules for oral use

Trial Locations (1)

LS2 9LH

(For Parts A and B) Covance Clinical Research Unit Ltd, Leeds

Sponsors

Lead Sponsor

Galecto Biotech AB
All Listed Sponsors
lead

Galecto Biotech AB

INDUSTRY